XENCOR,INC. (NASDAQ:XNCR) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition.

On May9, 2017, we announced our financial results for the quarter
ended March31, 2017 in the press release attached hereto as
Exhibit99.1 and incorporated herein by reference.

The information herein and in the exhibit hereto is being
furnished and shall not be deemed to be filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liability of that
section, nor shall such information be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

About XENCOR, INC. (NASDAQ:XNCR)

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.

XENCOR, INC. (NASDAQ:XNCR) Recent Trading Information

XENCOR, INC. (NASDAQ:XNCR) closed its last trading session up +0.30 at 24.10 with 143,223 shares trading hands.